Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 6/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10096876 | 0.84 | DRD2 (0.33) | DRD2ALDH1A1 | |
| SCHEMBL10096893 | 0.83 | KCNH2 (0.35) | — | |
| SCHEMBL10096825 | 0.74 | DRD2 (0.38) | DRD2MAOBPPARDLTA4HALDH1A1 | |
| SCHEMBL12083017 | 0.71 | PPARD (0.47) | DRD2MAOBPPARDLTA4HALDH1A1 | |
| SCHEMBL10097103 | 0.69 | DRD2 (0.40) | DRD2MAOBPPARDLTA4HALDH1A1 | |
| SCHEMBL2114367 | 0.68 | MAOB (0.40) | DRD2MAOBPPARDLTA4HALDH1A1 | |
| SCHEMBL11742464 | 0.68 | MAOB (0.40) | DRD2MAOBPPARDLTA4HPPARG | |
| SCHEMBL10097037 | 0.68 | DRD2 (0.39) | DRD2MAOBPPARDLTA4HALDH1A1 | |
| SCHEMBL10098123 | 0.67 | — | — | |
| SCHEMBL3443178 | 0.67 | TACR1 (0.40) | MAOBPPARDLTA4HALDH1A1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124196-B2 | Fluorobicyclo[2.2.2]octane compound, method of producing the same, and applications thereof | FUJIFILM CORPORATION (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20100231844-A1 | FLUOROBICYCLO[2.2.2]OCTANE COMPOUND, METHOD OF PRODUCING THE SAME, AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100231844-A1 | FLUOROBICYCLO[2.2.2]OCTANE COMPOUND, METHOD OF PRODUCING THE SAME, AND APPLICATIONS THEREOF | AFF2, FPR2, SLCO1A2 | DRD2 1385/4885MAOB 271/4885PPARD 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.